Scholarlink

Purpose of review <p>This review aims to clarify the role of exercise as a therapeutic intervention for metabolic dysfunction associated steatotic liver disease (MASLD). It addresses unresolved questions regarding optimal exercise modality, dose, progression, clinically meaningful outcomes, and integration with pharmacologic and multidisciplinary care, while translating recent international guideline recommendations into practical strategies. We put forward an innovative approach to be validated: REMEDHE.</p> Recent findings <p>Updated guidelines (EASL–EASD–EASO 2024; AASLD 2023) and recent randomized trials show that aerobic, resistance, and high-intensity interval training improve intrahepatic lipid content, liver enzymes, noninvasive fibrosis markers, cardiometabolic risk, and body composition, including sarcopenia and myosteatosis. Benefits occur even without weight loss, although variability in exercise prescriptions and outcome measures remains a challenge.</p> Summary <p>Exercise is a disease-modifying therapy in MASLD with multisystem benefits. Individualized, structured, and progressive programs are key. The proposed REMEDHE (REhabilitation for MEtabolic and hepatic Dysfunction) framework may standardize care, enhance implementation, and guide future research toward harmonized, clinically relevant endpoints.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prescribing Exercise in MASLD: From Evidence to a Structured, Measurable Intervention

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Leonardo Alberto Martinez Rodriguez,
  • Maria Renée Guevara Olivera,
  • Cesar Santiago Gutierrez Espinosa,
  • Yaisa Vargas Velazquez,
  • Jose Rolando Flores Lazaro,
  • Aldo Torre

摘要

Purpose of review

This review aims to clarify the role of exercise as a therapeutic intervention for metabolic dysfunction associated steatotic liver disease (MASLD). It addresses unresolved questions regarding optimal exercise modality, dose, progression, clinically meaningful outcomes, and integration with pharmacologic and multidisciplinary care, while translating recent international guideline recommendations into practical strategies. We put forward an innovative approach to be validated: REMEDHE.

Recent findings

Updated guidelines (EASL–EASD–EASO 2024; AASLD 2023) and recent randomized trials show that aerobic, resistance, and high-intensity interval training improve intrahepatic lipid content, liver enzymes, noninvasive fibrosis markers, cardiometabolic risk, and body composition, including sarcopenia and myosteatosis. Benefits occur even without weight loss, although variability in exercise prescriptions and outcome measures remains a challenge.

Summary

Exercise is a disease-modifying therapy in MASLD with multisystem benefits. Individualized, structured, and progressive programs are key. The proposed REMEDHE (REhabilitation for MEtabolic and hepatic Dysfunction) framework may standardize care, enhance implementation, and guide future research toward harmonized, clinically relevant endpoints.